Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

Joe_90_ Jan. 14 at 3:56 PM

$PHAT

0 · Reply

fgggggggg Jan. 14 at 3:34 PM

$PHAT

0 · Reply

Ecryder Jan. 14 at 3:23 PM

$PHAT

0 · Reply

Walleyeslayer Jan. 14 at 3:18 PM

$PHAT yahoo baby! This was my best stock of 2025 and will likely be my best stock of 2026. GL

0 · Reply

Quantumup Jan. 14 at 1:01 PM

Cantor reiterated Top Pick $PHAT at an Overweight rating and a $29 PT. Cantor said: As we enter a new calendar year, we are connecting with our companies under coverage to help set the stage for what to expect in 2026, and providing a refresher on our views. We spoke to PHAT management today (1/13), who pre-announced revenues for their potassium-competitive acid blocker or "PCAB" therapy, VOQUEZNA for H. pylori infection, erosive GERD and non-erosive GERD. 2025 sales are expected to come in around ~$175M and the company surpassed one million prescriptions dispensed in the U.S. since launch. PHAT expects to achieve operating profitability in 2H26, minus stock-based compensation. PHAT is one of our top picks.

0 · Reply

RunnerSignals Jan. 13 at 9:18 PM

Market Warriors $MREO $ERAS $GPCR $ANNX $PHAT Red at the open green at the close shook off sellers and finished strong

0 · Reply

brooklynyycc Jan. 13 at 7:47 PM

$PHAT shares short end of Dec significantly lower than previous month, any insight?

1 · Reply

sunset_PARK Jan. 13 at 7:22 PM

$PHAT the last piece of bad news about pcab competititor released yesterday, it should enter a positive read through time.

1 · Reply

Joe_90_ Jan. 13 at 5:17 PM

$PHAT all it takes is patience 😉

0 · Reply

StardustTrader Jan. 13 at 3:54 PM

$PHAT

0 · Reply

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 6 days ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 6 days ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Nov 21, 2025, 4:03 PM EST - 7 weeks ago

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Nov 4, 2025, 8:00 AM EST - 2 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Nov 3, 2025, 7:59 AM EST - 2 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 30, 2025, 1:26 PM EDT - 2 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 2 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 2 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Aug 20, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 10:51 PM EDT - 5 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:59 AM EDT - 5 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 7 months ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 7 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 7 months ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 7 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 1, 2025, 12:09 PM EDT - 9 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 9 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 9 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 10 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 11 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 11 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 11 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Joe_90_ Jan. 14 at 3:56 PM

$PHAT

0 · Reply

fgggggggg Jan. 14 at 3:34 PM

$PHAT

0 · Reply

Ecryder Jan. 14 at 3:23 PM

$PHAT

0 · Reply

Walleyeslayer Jan. 14 at 3:18 PM

$PHAT yahoo baby! This was my best stock of 2025 and will likely be my best stock of 2026. GL

0 · Reply

Quantumup Jan. 14 at 1:01 PM

0 · Reply

RunnerSignals Jan. 13 at 9:18 PM

Market Warriors $MREO $ERAS $GPCR $ANNX $PHAT Red at the open green at the close shook off sellers and finished strong

0 · Reply

brooklynyycc Jan. 13 at 7:47 PM

$PHAT shares short end of Dec significantly lower than previous month, any insight?

1 · Reply

sunset_PARK Jan. 13 at 7:22 PM

$PHAT the last piece of bad news about pcab competititor released yesterday, it should enter a positive read through time.

1 · Reply

Joe_90_ Jan. 13 at 5:17 PM

$PHAT all it takes is patience 😉

0 · Reply

StardustTrader Jan. 13 at 3:54 PM

$PHAT

0 · Reply

ZorroX Jan. 13 at 1:51 PM

$PHAT Do we know if that offering has priced at $16 or perhaps the market is forcing them to lower it?

1 · Reply

BullRunx100 Jan. 12 at 8:42 PM

$PHAT a dip like this will soon follow a rip!

1 · Reply

longshot45 Jan. 12 at 4:19 PM

$PHAT I guess we find out tomorrow or wednesday how much of the offering was bought up. Should make for an interesting week

0 · Reply

HoosierDaddy79 Jan. 12 at 3:15 PM

$PHAT if you believe the $18/$1.26B market cap prior to the offering was reasonable, the diluted SP should be in the $16 range. It will recover. This is a gift for the shorts that won’t last long. Their Q4 report is indicating they are very close to profitable. Smart to nab some operating cash now, rather than increasing debt, to further investigate additional indications. This wasn’t a huge offering.

2 · Reply

Walleyeslayer Jan. 12 at 3:13 PM

$PHAT I would think there still has to be shorts that are caught this level. Would be surprised if they hit it hard to find some stop losses and then maybe the big run. No more ads for me until we see a clear bottom.

1 · Reply

JP2024 Jan. 12 at 3:05 PM

$PHAT its just about patience usually when a company issues more shares and stock tanks like this … im out but i only sold 20 % last week but the 80 % that im riding is painful but i believe in the company / medication

0 · Reply

StardustTrader Jan. 12 at 2:56 PM

$PHAT 20day weekly is at 14, should bounce here. Hard zone to find good adds in...

0 · Reply

Walleyeslayer Jan. 12 at 2:47 PM

$PHAT low volume moves. Where will we see a bottom. ??

0 · Reply

Withermania Jan. 9 at 1:35 PM

$PHAT loading the boat down here. This team is primed for 2026. Legacy PPIs are dying, PHAT starting to rip. Let’s gooo

0 · Reply

fgggggggg Jan. 9 at 1:14 PM

$PHAT over a million prescriptions!! Anyone have the chart?

0 · Reply

GSTX7 Jan. 8 at 9:00 PM

$PHAT Back in. Starter at $15.5. Will add every 5% down from here...

0 · Reply

StardustTrader Jan. 8 at 8:14 PM

$PHAT tempting add....

0 · Reply

Market Cap	1.03B
Revenue (ttm)	55.25M
Net Income (ttm)	-334.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-605.12%
Debt to Equity Ratio	-0.49

Volume	1,428,200
Avg Vol	1,058,468
Day's Range	N/A - N/A
Shares Out	71.42M
Stochastic %K	43%
Beta	0.48
Analysts	Strong Sell
Price Target	$22.90